Group 1 - The core viewpoint of the article highlights that Mingchen Health (SZ 002919) held its fourth board meeting on October 28, 2025, to discuss the proposal for the second extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, Mingchen Health's revenue composition was 76.84% from software and information technology services and 23.16% from the manufacturing of chemical raw materials and products [1] - As of the report, Mingchen Health has a market capitalization of 4.8 billion yuan [1] Group 2 - The article also notes that the A-share market has surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with technology leading the market's transformation [1] - This shift is characterized as the beginning of a "slow bull" market pattern [1]

证券代码：002919 证券简称：名臣健康 公告编号：2025-040 名臣健康用品股份有限公司 关于聘任会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、原聘任会计师事务所名称：致同会计师事务所（特殊普通合伙）（以下 简称"致同所"）； 拟聘任会计师事务所名称：广东司农会计师事务所（特殊普通合伙）（以下 简称"司农会计师事务所"）。 拟变更会计师事务所的原因：鉴于致同所已连续多年为公司提供审计服务， 其服务期限届满。根据财政部、国务院国资委、证监会印发的《国有企业、上市 公司选聘会计师事务所管理办法》（财会〔2023〕4 号）（以下简称"选聘管理 办法"）的相关要求，为进一步提升公司审计工作的独立性和客观性，充分保障 公司审计工作安排，基于审慎性原则以及公司对审计服务的需求，公司通过采用 竞争性谈判的方式拟聘任司农会计师事务所为公司 2025 年度财务报告审计机构 和内部控制审计机构。 公司就变更会计师事务所相关事项与致同所进行了充分沟通，双方均已确认 就本次变更会计师事务所事项无异议。致同所在为公司提供审计服务期间，勤勉、 ...

关于召开 2025 年第二次临时股东会的通知 证券代码：002919 证券简称：名臣健康 公告编号：2025-041 名臣健康用品股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重 大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 2、股东会的召集人：董事会 6、会议的股权登记日：2025 年 11 月 10 日 7、出席对象： （1）在股权登记日持有公司股份的股东或其代理人； 本次股东会的股权登记日为 2025 年 11 月 10 日，于股权登记日下午 15:00 收市时在中国结算深圳 分公司登记在册的公司全体股东均有权出席股东会。不能出席会议的股东，可以以书面形式委托代理人 出席本次股东会（授权委托书见附件 1），该代理人不必是本公司股东。 （2）公司董事、监事和高级管理人员； 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会 ...

证券代码：002919 证券简称：名臣健康 公告编号：2025-038 名臣健康用品股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 名臣健康用品股份有限公司(以下简称"公司")第四届董事会第七次会议于 2025年10月28日在公司二楼会议室以现场和视频通讯方式召开，会议通知以专人 送达、传真、电子邮件、电话相结合的方式已于2025年10月17日向各位董事发出。 本次会议由董事长兼总经理陈建名先生主持。本次会议应出席董事7名，实际出 席董事7名(其中：董事梁锦辉先生,独立董事高慧先生、陈景华先生、吴小艳女 士以通讯方式参会)。本次会议的召开符合《公司法》《公司章程》等法律法规 的规定，合法有效。 二、董事会会议审议情况 1、审议通过《关于<2025 年第三季度报告>的议案》 表决结果：有效表决 7 票，同意票 7 票，反对票 0 票，弃权票 0 票。 经审核，董事会认为，公司 2025 年第三季度报告的内容真实、准确、完整 地反映了公司 2025 年第三季度经营的实际情况，不存在任何虚假记载、 ...

Core Insights - The company reported third-quarter revenue of 367 million yuan, representing a year-on-year increase of 14.73% [1] - Net profit for the third quarter was 1.4872 million yuan, showing a significant year-on-year decline of 95.92% [1] - For the first three quarters, the company achieved revenue of 1.079 billion yuan, which is a year-on-year growth of 9.56% [1] - Net profit for the first three quarters was 42.5498 million yuan, reflecting a year-on-year decrease of 56.03% [1]

Revenue and Profitability - Revenue for Q3 2025 reached ¥367,205,252.81, an increase of 14.73% compared to the same period last year[5] - Net profit attributable to shareholders decreased by 95.92% to ¥1,487,200.83, while the net profit after deducting non-recurring gains and losses fell by 98.79% to ¥453,149.64[5] - Total operating revenue for the current period reached ¥1,078,874,052.86, an increase of 9.57% compared to ¥984,704,973.19 in the previous period[26] - Net profit for the current period was ¥42,403,252.01, a decrease of 56.14% from ¥96,790,316.11 in the previous period[27] - Basic earnings per share for the current period were ¥0.1596, down from ¥0.3631 in the previous period[28] Assets and Liabilities - Total assets as of September 30, 2025, amounted to ¥1,172,132,210.48, reflecting a growth of 6.23% from the end of the previous year[5] - Total assets increased to ¥1,172,132,210.48, compared to ¥1,103,346,118.01 in the previous period, reflecting a growth of 6.26%[24] - Total liabilities rose to ¥350,698,567.24, an increase of 25.14% from ¥280,009,676.12 in the previous period[24] - The company’s intangible assets increased by 92.14% to ¥291,065,108.53, reflecting ongoing development projects[9] - Deferred income tax assets increased to ¥91,267,889.99 from ¥76,855,644.74, marking a rise of 18.67%[24] Cash Flow - The company reported a 29.60% decline in net cash flow from operating activities, totaling ¥39,902,804.53 for the year-to-date[13] - Operating cash inflow for the current period was CNY 928,187,653.55, a slight increase from CNY 922,951,805.76 in the previous period[29] - Net cash outflow from operating activities was CNY 39,902,804.53, down from CNY 56,678,574.83 in the previous period[30] - Cash inflow from investment activities totaled CNY 238,666,204.95, compared to CNY 149,815,082.81 in the previous period[30] - Cash inflow from financing activities was CNY 30,014,544.16, with a net cash outflow of CNY 26,491,701.20, compared to a net outflow of CNY 49,781,796.36 in the previous period[30] Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,452[15] - The largest shareholder, Chen Qinfang, holds 35.02% of shares, totaling 93,338,604 shares, with 14,644,000 shares pledged[15] - The company plans to repurchase shares using its own funds, with a total repurchase amount between RMB 30 million and RMB 50 million, at a price not exceeding RMB 23 per share[18] - As of September 30, 2025, the company has repurchased a total of 2,249,700 shares, representing 0.84% of the total share capital[20] Operating Costs and Expenses - Total operating costs amounted to ¥1,031,137,681.82, up 21.06% from ¥852,236,672.12 in the prior period[26] - The company’s financial expenses surged by 205.99% to ¥398,255.73, primarily due to reduced foreign exchange gains[12] - Research and development expenses for the current period were ¥40,483,039.47, down 17.16% from ¥48,895,920.66 in the previous period[27] - Cash paid for purchasing goods and services was CNY 622,079,280.28, an increase from CNY 583,529,139.50 in the previous period[30] - Cash paid to employees decreased to CNY 144,728,270.05 from CNY 171,317,281.65 in the previous period[30] Accounts Receivable and Payable - The company’s accounts payable rose by 57.66% to ¥200,334,768.73, driven by increased game distribution and publishing costs[9] - The company reported a significant increase in accounts payable, which rose to ¥200,334,768.73 from ¥127,066,568.53, representing a growth of 57.59%[24] - Accounts receivable decreased from RMB 241,718,639.65 to RMB 236,124,451.25 during the reporting period[21] - Prepayments decreased from RMB 124,671,876.03 to RMB 80,890,476.44[21] Other Information - The company has not disclosed any significant new product developments or market expansions in the current reporting period[18] - There are no reported changes in the top 10 shareholders due to share lending or borrowing activities[16]

Core Points - The gaming sector experienced a decline of 1.29% on October 16, with Mingchen Health leading the drop [1] - The Shanghai Composite Index closed at 3916.23, up 0.1%, while the Shenzhen Component Index closed at 13086.41, down 0.25% [1] Stock Performance - The table shows various gaming stocks with their closing prices, percentage changes, trading volumes, and transaction amounts, indicating mixed performance among individual stocks [1] - Notable declines include: - 37 Interactive Entertainment down 1.33% [1] - Glacier Network down 1.38% [1] - Yaoji Technology down 1.47% [1] - Conversely, ST Dazheng and ST Kaiwen showed slight increases of 0.99% and 0.26% respectively [1] Capital Flow - The gaming sector saw a net outflow of 833 million yuan from major funds, while retail investors contributed a net inflow of 628 million yuan [3] - Speculative funds recorded a net inflow of 205 million yuan [3]

New Stock Issuance - New stock issuance includes 泰凯英 (code: 920020) at an issuance price of 7.50 and 超颖电子 (code: 732175) at 17.08[1] Equity Market Alerts - 上纬新材 (code: 688585) is undergoing a tender offer from September 29, 2025, to October 28, 2025[1] - 科思科技 (code: 688788) and 博瑞医药 (code: 688166) have recent announcements dated September 26, 2025, and October 10, 2025, respectively[1] - 南新制药 (code: 688189) reported severe abnormal fluctuations on October 10, 2025[1] Trading Alerts - A total of 50 stocks have trading alerts with the latest announcements on October 15, 2025, including 国光连锁 (code: 605188) and 中持股份 (code: 603903)[1] - The lowest trading alert price recorded is 1,116 for 赛恩斯 (code: 688480)[1]

Core Viewpoint - Mingchen Health has seen a stock price increase of 5.41%, reaching 18.51 CNY per share, with a trading volume of 214 million CNY and a turnover rate of 4.52%, resulting in a total market capitalization of 4.933 billion CNY [1] Group 1: Company Overview - Mingchen Health Products Co., Ltd. is located in the Lian Nan Industrial Zone, Chenghai District, Shantou City, Guangdong Province, and was established on December 14, 1994, with its listing date on December 18, 2017 [1] - The company's main business involves the research, development, production, and sales of health care products, including shampoos, conditioners, shower gels, gel water, and skincare products [1] - The revenue composition of the main business is as follows: 76.84% from online games, 23.09% from daily chemical products, and 0.07% from other sources [1] Group 2: Fund Holdings - According to data from the top ten holdings of funds, one fund under Jiashi Fund has a significant position in Mingchen Health [2] - Jiashi Runze Quantitative Regular Mixed Fund (005167) held 15,000 shares in the second quarter, with no change in the number of shares held compared to the previous period, accounting for 0.84% of the fund's net value, ranking as the seventh largest holding [2] - The estimated floating profit for today is approximately 14,300 CNY [2] Group 3: Fund Manager Information - The fund manager of Jiashi Runze Quantitative Regular Mixed Fund (005167) is Lai Lihui [3] - As of the report date, Lai Lihui has a cumulative tenure of 4 years and 363 days, with the total asset size of the fund being 3.499 billion CNY [3] - The best fund return during Lai's tenure is 30.87%, while the worst return is 0.16% [3]

Group 1 - The stock of Mingchen Health Products Co., Ltd. (stock code: 002919) experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days (October 10, 2025, October 13, 2025, and October 14, 2025) [2] - The company's board confirmed that there were no significant undisclosed matters that could have impacted the stock price, and the company's recent operational conditions remained normal without major changes in the internal and external business environment [3][4] - The company has established a wholly-owned subsidiary, Fujian Xingxuan Shikong Network Technology Co., Ltd., with an investment of RMB 10 million, and the subsidiary has completed its business registration [6]